Pharmaron

Haixin zhihui is an artificial intelligence company. They offer intelligent diagnosis, and treatment systems for tumor diseases have been developed. They provide patients with precise treatment recommendations and assist patients in treatment planning and full disease management.

Shanghai Jiying uses intelligent technology, focusing on data analysis and AI algorithms.

Rxilient is a company that specializes in providing contract development and manufacturing organization (CDMO) services for the pharmaceutical sector. It manufactures and distributes a range of pharmaceutical products aimed at addressing unmet medical, health, and beauty needs. The company offers a comprehensive portfolio of dermatology and medical aesthetic products, developed with a scientific approach, to support its clients in meeting various requirements for skin health and aesthetics. Through its services, Rxilient aims to enhance the effectiveness and accessibility of health and beauty solutions in the market.

Allergan Biologics developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Absorption Systems is a company that specializes in providing non-clinical contract research organization (CRO) services, focusing on the prediction of human outcomes related to drug absorption, distribution, metabolism, and excretion. With locations in Exton, Pennsylvania, San Diego, California, and Panama City, Panama, the company serves a diverse clientele, including small virtual pharmaceutical firms, large pharmaceutical companies, and specialty CROs seeking complementary services. Absorption Systems emphasizes a collaborative approach, working closely with clients to design studies and develop custom models tailored to their specific needs. This flexibility has fostered innovative solutions in drug discovery and development, enhancing the capabilities of pharmaceutical, biotech, and medical device companies, as well as regulatory agencies in their research and testing efforts.

Xceleron, founded in 1997 in York, UK, and now based in Germantown, Maryland, specializes in bioanalytical accelerator mass spectrometry (AMS) services to enhance drug development. The company pioneered techniques for human microdosing and microtracing, focusing on the pharmacokinetics and metabolism of developmental drugs during early clinical trial phases. Xceleron's services include micro-dosing, preclinical evaluation, intravenous pharmacokinetics, metabolite profiling, and mass balance investigations in humans. Their expertise is particularly valuable given the complexity of modern small molecules, which often exhibit low solubility and lengthy half-lives, necessitating early pharmacokinetic characterization to improve the cost-effectiveness of clinical development. Through a commitment to integrity and collaboration, Xceleron aims to accelerate the delivery of life-changing products to the market.

Quotient Bioresearch Limited is a contract research organization (CRO) based in Rushden, United Kingdom, specializing in early-stage and specialized drug development services for clients in the pharmaceutical, biotechnology, agrochemical, chemical, and animal health sectors. The company offers a comprehensive range of services, including integrated chemistry and metabolism programs, radiochemistry, drug metabolism, and environmental fate solutions. Its capabilities encompass tritium and stable isotope synthesis, carbon-14 synthesis, preclinical drug metabolism and pharmacokinetics (DMPK), metabolite analysis, and bioanalysis. Quotient Bioresearch provides tailored solutions to address the specific needs of its diverse clientele, leveraging advanced scientific, chemical, and biological expertise. Founded in 1992, the company operates as a subsidiary of Pharmaron, Inc., and has established a reputation for delivering high-quality services globally.

Bridge Laboratories, Inc. operates as a preclinical contract research organization. Its drug development and preclinical services include short and long-term in vivo studies ranging from acute to carcinogenicity protocols; and species and routes of administration.